iloprost

Iloprost (Ciloprost) is a stabilized synthetic analog of prostaglandin I2, an inhibitor of platelet aggregation and vasodilation, used in the study of cardiovascular disease.

(Z)-Iloprost ((Z)-Ciloprost; (Z)-ZK 36374) is a vasodilator that can prevent platelet activation induced by heparin.

15-KetoIloprost is the C-15 oxidized derivative of Iloprost. Iloprost (ZK 36374) acts as a prostacyclin (PGI2) analog, playing a role in embryonic development, alleviating inflammation, and inhibiting tumor metastasis.

Iloprost is a second generation structural analog of prostacyclin (PGI2) with about ten-fold greater potency than the first generation stable analogs, typified by carbaprostacyclin. Iloprost binds with equal affinity to the recombinant human IP and EP1 receptors with a Ki value of 11 nM. Most preparations of iloprost contain 16(S) and 16(R) stereoisomers. 16(R)-Iloprost inhibits platelet aggregation with an IC50 value of 65 nM.

5-cis-15(R)-Iloprost (5-cis-15(R)-Ciloprost) is the C-5 cis-isomer and 15(R)-epimer isomer of Iloprost. Iloprost, a prostacyclin (PGI2) analog, plays a role in embryonic development, alleviates inflammation, and inhibits tumor metastasis. Additionally, Iloprost is applicable in peripheral vascular research.

Iloprost is a second generation structural analog of prostacyclin (PGI2) with about ten-fold greater potency than the first generation stable analogs, typified by carbaprostacyclin. Iloprost binds with equal affinity to the recombinant human IP and EP1 receptors with a Ki value of 11 nM. Most preparations of iloprost contain 16(S) and 16(R) stereoisomers. 16(S)-Iloprost potently inhibits platelet aggregation with an IC50 value of 3.5 nM.

sulotroban is a TXA2 receptor antagonist that acts synergistically with iloprost to inhibit TXA2-dependent platelet activation.

CAY10449 is an antagonist of the I prostanoid receptor. It is capable of reversing the decrease in transepithelial electrical resistance (TEER) induced by iloprost. Additionally, CAY10449 can counteract the effects of ONO-1301 in mouse models. This compound is useful for research in asthma and allergic airway inflammation.

Epoxyeicosatrienoic acids (EETs), such as 11(12)-EET and 14(15)-EET, are cytochrome P450 metabolites of arachidonic acid that have been identified as endothelium-derived hyperpolarizing factors with vasodilator activity. 14,15-EE-5(Z)-E is a structural analog of 14,15-epoxyeicosatrienoic acids (14,15-EET) that antagonizes EET-induced relaxation of vascular smooth muscle. Relaxation of U46619-constricted bovine arteries by 14,15-EET could be inhibited approximately 80% by 14,15-EE-5(Z)-E at a concentration of 10 μM. 14,15-EE-5(Z)-E does not appear to antagonize nitric oxide- or iloprost-mediated vascular relaxation.

RO1138452 (CAY10441) is a selective and orally bioavailable antagonist of prostacyclin receptor (pKi: 8.3). It antagonizes the carbaprostacyclin-induced activation of human neuroblastoma adenylate cyclase, blocking cyclic AMP accumulation in a dose-dependent manner. Likewise, it inhibits the binding of tritiated iloprost to rodent neuroblastoma cells with a Ki of about 1.5 nM. At levels between 2-20 mg/kg in rats, CAY10441 shows significant analgesic activity in standard antinociceptive assays [1].

BMY-42393 is orally active and selective platelet aggregation inhibitor. BMY-42393 is also a prostacyclin partial agonist that inhibited ADP, collagen and thrombin-induced platelet aggregation (IC50 range 0.3 - 2.0 microM). BMY-42393 stimulated platelet adenylate cyclase activity (EC50 = 25 nM). Platelets treated with BMY 42393 showed an elevation of cAMP levels and activation of cAMP-dependent protein kinase. BMY 42393 also inhibited thrombin-induced elevation of intracellular free calcium. BMY 42393 competed for radiolabeled iloprost and PGE1 binding to platelet membranes (IC50; 170 nM and 130 nM, respectively).